Skip to main content

Drug Interactions between plasminogen, human and prasugrel

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Major

prasugrel plasminogen, human

Applies to: prasugrel and plasminogen, human

MONITOR CLOSELY: Coadministration of plasminogen with anticoagulants, antiplatelets, or other agents that interfere with normal coagulation may prolong or worsen bleeding from active lesions and wounds. Plasminogen deficiency type 1 is characterized by the formation of fibrin-rich lesions on mucous membranes. Replacement therapy temporarily corrects plasminogen deficiency and reduces or resolves extravascular fibrinous lesions, which may prolong or worsen bleeding from any active lesion (disease-related or not), including GI bleeding, hemoptysis, epistaxis, vaginal bleeding, or hematuria. Clinical data are currently lacking.

MANAGEMENT: Caution is advised if plasminogen is used in patients taking anticoagulants, antiplatelets, or other agents that interfere with normal coagulation. Clinical and laboratory monitoring are recommended for 4 hours after infusion. If a patient develops any GI bleeding or bleeding from any other site that persists longer than 30 minutes, seek emergency care and discontinue plasminogen immediately.

References (1)
  1. (2022) "Product Information. Ryplazim (plasminogen, human)." Prometic Biotherapeutics Inc

Drug and food interactions

No alcohol/food interactions were found. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer